JP2021534116A5 - - Google Patents

Info

Publication number
JP2021534116A5
JP2021534116A5 JP2021506718A JP2021506718A JP2021534116A5 JP 2021534116 A5 JP2021534116 A5 JP 2021534116A5 JP 2021506718 A JP2021506718 A JP 2021506718A JP 2021506718 A JP2021506718 A JP 2021506718A JP 2021534116 A5 JP2021534116 A5 JP 2021534116A5
Authority
JP
Japan
Prior art keywords
alkyl
use according
heteroaryl
alkenyl
aralkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021506718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534116A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/046408 external-priority patent/WO2020036997A1/en
Publication of JP2021534116A publication Critical patent/JP2021534116A/ja
Publication of JP2021534116A5 publication Critical patent/JP2021534116A5/ja
Pending legal-status Critical Current

Links

JP2021506718A 2018-08-14 2019-08-13 再発性の濾胞性リンパ腫の処置 Pending JP2021534116A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862718926P 2018-08-14 2018-08-14
US62/718,926 2018-08-14
US201962836507P 2019-04-19 2019-04-19
US62/836,507 2019-04-19
PCT/US2019/046408 WO2020036997A1 (en) 2018-08-14 2019-08-13 Treatment of relapsed follicular lymphoma

Publications (2)

Publication Number Publication Date
JP2021534116A JP2021534116A (ja) 2021-12-09
JP2021534116A5 true JP2021534116A5 (enExample) 2022-08-19

Family

ID=69525835

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021506718A Pending JP2021534116A (ja) 2018-08-14 2019-08-13 再発性の濾胞性リンパ腫の処置

Country Status (14)

Country Link
US (1) US20210196725A1 (enExample)
EP (1) EP3836936A4 (enExample)
JP (1) JP2021534116A (enExample)
KR (1) KR20210043637A (enExample)
CN (1) CN112839659A (enExample)
AU (1) AU2019321526A1 (enExample)
BR (1) BR112021002734A2 (enExample)
CA (1) CA3109377A1 (enExample)
IL (1) IL280721A (enExample)
MA (1) MA53237A (enExample)
MX (1) MX2021001765A (enExample)
SG (1) SG11202101417XA (enExample)
TW (1) TW202021593A (enExample)
WO (1) WO2020036997A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107501241B (zh) 2011-03-28 2020-10-13 梅制药公司 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途
EP3630118A4 (en) 2017-05-23 2021-03-31 MEI Pharma, Inc. COMBINATION THERAPY
MX2020001727A (es) 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2919869B1 (fr) * 2007-08-09 2009-09-25 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
CN107501241B (zh) * 2011-03-28 2020-10-13 梅制药公司 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途
UA116544C2 (uk) * 2012-08-09 2018-04-10 Селджин Корпорейшн Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
MA38462A1 (fr) * 2013-04-08 2017-10-31 Bayer Pharma AG Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement de lymphomes
CA2979671C (en) * 2014-09-23 2020-03-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
CN109982687A (zh) * 2016-09-19 2019-07-05 梅制药公司 联合疗法
MX2020001727A (es) * 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.

Similar Documents

Publication Publication Date Title
JP6434482B2 (ja) 置換アシルアニリドおよびそれらの使用方法
JP2022520061A5 (enExample)
JP2015536986A5 (enExample)
JP2014500870A5 (enExample)
JP2014528464A5 (enExample)
JP2024156774A5 (enExample)
CN102497864B (zh) 用于预防或治疗由化疗诱发的疼痛的σ配体
JP2020528889A5 (enExample)
JP2018523689A5 (enExample)
JP2018514544A5 (enExample)
JP2017505314A (ja) Hbv感染の治療のための併用療法
US9889110B2 (en) Selective androgen receptor modulator for treating hormone-related conditions
JP2022550919A5 (enExample)
US10662148B2 (en) Selective androgen receptor modulator and methods of use thereof
JP2010503620A5 (enExample)
JP2019529460A5 (enExample)
JP2022508513A5 (enExample)
JP2020531414A5 (enExample)
JP2016516792A (ja) α−2アドレノレセプターおよびシグマレセプターリガンドの組み合わせ物
JP2023548190A5 (enExample)
WO2015061724A1 (en) Selective androgen receptor modulator and chemotherapeutic agent for treating muscle wasting in cancer patients
JP2021534115A5 (enExample)
JP2024516430A5 (enExample)
JP2025509278A5 (enExample)
JP7357386B2 (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用